SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
PR Newswire · 06/26 10:30
8 Stock Catalysts For The Week Ahead
The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week. Here are eight potential catalysts coming this week that could move the markets.
Benzinga · 06/22 15:30
Aridis's AR-501 shows positive effect in early-stage study
Seeking Alpha - Article · 06/22 15:17
Aridis Reports Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial of AR-501
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today positive results from the Phase 1 portion of its Phase 1/2a clinical trial of AR-501, an inhaled formulation of gallium citrate being developed for the treatment of chronic lung infections in patients
Benzinga · 06/22 10:20
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today positive results from the Phase 1 portion of its Phase 1/2
PR Newswire · 06/22 09:30
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
Biotech stocks rebounded along with the broader market in the week ended June 19.
Benzinga · 06/21 18:53
Aridis Pharmaceuticals to Discuss APEX in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
PR Newswire · 06/18 10:30
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
PR Newswire · 06/15 10:30
ACB, CHK, CODX and SAVA among midday movers
Seeking Alpha - Article · 05/15 16:40
H.C. Wainwright Reiterates Buy on Aridis Pharmaceuticals, Raises Price Target to $11
H.C. Wainwright analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and raises the price target from $7 to $11.
Benzinga · 05/15 11:22
Aridis Pharmaceuticals EPS misses by $0.19
Aridis Pharmaceuticals (NASDAQ:ARDS): Q1 GAAP EPS of -$0.73 misses by $0.19. Cash and cash equivalents of $16.3M. Press Release
seekingalpha · 05/13 01:28
Aridis Pharmaceuticals Announces First Quarter 2020 Results
PR Newswire · 05/12 21:05
Aridis Pharmaceuticals Q1 EPS $(0.730) Up From $(0.990) YoY
Aridis Pharmaceuticals (NASDAQ:ARDS) reported quarterly losses of $(0.730) per share. This is a 26.26 percent increase over losses of $(0.990) per share from the same period last year.
Benzinga · 05/12 20:10
Will Aridis Pharmaceuticals Continue to Surge Higher?
Zacks · 05/07 17:08
PTLA, TGTX, NCLH and HTZ among midday movers
Seeking Alpha - Article · 05/05 16:42
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
PR Newswire · 04/29 10:30
Aridis Pharmaceuticals EPS beats by $0.17
seekingalpha · 04/09 02:04
Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update
PR Newswire · 04/08 20:59
Key events next week - healthcare
Seeking Alpha - Article · 03/06 13:09
Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference
PR Newswire · 03/05 10:30